CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-11-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V106.11.790.790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• therapy in patients with chronic myelomonocytic leukemia Induction of hypomethylation and molecular response after decitabine

  2013cites this paper
• The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients

  2012cites this paper
• DNA-Methylierungsdynamik bei fünf Patienten mit akuter myeloischer Leukämie unter 5-Aza-2-Deoxycytidin-Therapie

  2011cites this paper
• Targeted Therapy in Acute Myelogenous Leukemia

  2008cites this paper
• Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.

  2008cites this paper
• New drugs in acute myeloid leukemia.

  2008cites this paper
• DNA Methylation as an Epigenetic Factor in the Development and Progression of Polycythemia Vera

  2008cites this paper
• myelodysplastic syndromes: pharmacodynamic, mechanistic and clinical studies

  2007cites this paper
• DNA methylation and 5-azacytidine in myelodysplastic syndromes : Pharmacodynamic, mechanistic and clinical studies

  2007cites this paper
• Treatment Options in Advanced Myelodysplastic Syndrome, with Emphasis on Epigenetic Therapy

  2007cites this paper
• Decitabine--bedside to bench.

  2007cites this paper
• Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.

  2007cites this paper